;PMID: 12124804
;source_file_695.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:44..173] = [t:44..173]
;2)section:[e:177..276] = [t:177..276]
;3)section:[e:280..392] = [t:280..392]
;4)sentence:[e:396..526] = [t:396..526]
;5)sentence:[e:527..877] = [t:527..877]
;6)sentence:[e:878..1017] = [t:878..1017]
;7)sentence:[e:1018..1158] = [t:1018..1158]
;8)sentence:[e:1159..1278] = [t:1159..1278]
;9)sentence:[e:1279..1347] = [t:1279..1347]
;10)sentence:[e:1348..1512] = [t:1348..1512]
;11)sentence:[e:1513..1717] = [t:1513..1717]
;12)sentence:[e:1718..1771] = [t:1718..1771]
;13)sentence:[e:1772..1872] = [t:1772..1872]
;14)sentence:[e:1873..2110] = [t:1873..2110]
;15)section:[e:2111..2143] = [t:2111..2143]
;16)section:[e:2147..2192] = [t:2147..2192]

;section 0 Span:0..39
;Int J Cancer  2002 Aug 10;100(5):549-56
(SEC
  (FRAG (NNP:[0..3] Int) (NNP:[4..5] J) (NNP:[6..12] Cancer) (CD:[14..18] 2002)
        (NNP:[19..22] Aug) (CC:[23..30] 10;100-LRB-) (CD:[30..31] 5)
        (-RRB-:[31..32] -RRB-) (CD:[32..36] :549) (::[36..37] -)
        (CD:[37..39] 56)))

;sentence 1 Span:44..173
;Molecular genetic analysis of malignant melanomas for aberrations of the WNT 
;signaling pathway genes CTNNB1, APC, ICAT and BTRC.
;[74..93]:malignancy:"malignant melanomas"
;[117..120]:gene-generic:"WNT"
;[146..152]:gene-rna:"CTNNB1"
;[154..157]:gene-rna:"APC"
;[159..163]:gene-rna:"ICAT"
;[168..172]:gene-rna:"BTRC"
(SENT
  (NP-HLN
    (NP (JJ:[44..53] Molecular) (JJ:[54..61] genetic) (NN:[62..70] analysis))
    (PP (IN:[71..73] of)
      (NP
        (NP (JJ:[74..83] malignant) (NNS:[84..93] melanomas))
        (PP (IN:[94..97] for)
          (NP
            (NP (NNS:[98..109] aberrations))
            (PP (IN:[110..112] of)
              (NP
                (NP (DT:[113..116] the)
                  (NML (NN:[117..120] WNT) (NN:[122..131] signaling)
                       (NN:[132..139] pathway))
                  (NNS:[140..145] genes))
                (NP (NN:[146..152] CTNNB1) (,:[152..153] ,) (NN:[154..157] APC)
                    (,:[157..158] ,) (NN:[159..163] ICAT) (CC:[164..167] and)
                    (NN:[168..172] BTRC))))))))
    (.:[172..173] .)))

;section 2 Span:177..276
;Reifenberger J, Knobbe CB, Wolter M, Blaschke B, Schulte KW, Pietsch T,
;Ruzicka  T, Reifenberger G.
(SEC
  (FRAG (NNP:[177..189] Reifenberger) (NNP:[190..192] J,)
        (NNP:[193..199] Knobbe) (NNP:[200..202] CB) (,:[202..203] ,)
        (NNP:[204..210] Wolter) (NNP:[211..213] M,) (NNP:[214..222] Blaschke)
        (NNP:[223..224] B) (,:[224..225] ,) (NNP:[226..233] Schulte)
        (NNP:[234..236] KW) (,:[236..237] ,) (NNP:[238..245] Pietsch)
        (NNP:[246..247] T) (,:[247..248] ,) (NNP:[249..256] Ruzicka)
        (NNP:[258..259] T) (,:[259..260] ,) (NNP:[261..273] Reifenberger)
        (NNP:[274..276] G.)))

;section 3 Span:280..392
;Department of Dermatology, Heinrich-Heine-University, Dusseldorf, Germany. 
;reifenbergerj@med.uni-duesseldorf.de
(SEC
  (FRAG (NNP:[280..290] Department) (IN:[291..293] of)
        (NNP:[294..305] Dermatology) (,:[305..306] ,) (NNP:[307..315] Heinrich)
        (::[315..316] -) (NNP:[316..321] Heine) (::[321..322] -)
        (NNP:[322..332] University) (,:[332..333] ,) (NNP:[334..344] Dusseldorf)
        (,:[344..345] ,) (NNP:[346..353] Germany) (.:[353..354] .)
        (``:[356..373] reifenbergerj@med) (NN:[373..377] .uni) (::[377..378] -)
        (NN:[378..389] duesseldorf) (.:[389..392] .de)))

;sentence 4 Span:396..526
;Aberrant activation of the Wnt signaling pathway has been reported in
;different  human tumor types, including malignant melanomas.
;[423..426]:gene-generic:"Wnt"
;[506..525]:malignancy:"malignant melanomas"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[396..404] Aberrant) (NN:[405..415] activation))
      (PP (IN:[416..418] of)
        (NP (DT:[419..422] the) (NN:[423..426] Wnt) (NN:[427..436] signaling)
            (NN:[437..444] pathway))))
    (VP (VBZ:[445..448] has)
      (VP (VBN:[449..453] been)
        (VP (VBN:[454..462] reported)
          (NP-1 (-NONE-:[462..462] *))
          (PP (IN:[463..465] in)
            (NP
              (NP (JJ:[466..475] different) (JJ:[477..482] human)
                  (NN:[483..488] tumor) (NNS:[489..494] types))
              (,:[494..495] ,)
              (PP (VBG:[496..505] including)
                (NP (JJ:[506..515] malignant) (NNS:[516..525] melanomas))))))))
    (.:[525..526] .)))

;sentence 5 Span:527..877
;We investigated 37 malignant  melanomas (15 primary tumors and 22 metastases)
;for alterations of 4 genes  encoding members of this pathway, i.e., CTNNB1
;(beta-catenin gene, 3p22.1), APC  (adenomatous polyposis coli gene, 5q22.2),
;BTRC (beta-transducin  repeat-containing protein gene, 10q24.3) and ICAT
;(inhibitor of beta-catenin and  Tcf-4, 1p36.2).
;[546..566]:malignancy:"malignant  melanomas"
;[571..585]:malignancy:"primary tumors"
;[593..603]:malignancy:"metastases"
;[626..631]:gene-rna:"genes"
;[673..679]:gene-rna:"CTNNB1"
;[681..693]:gene-rna:"beta-catenin"
;[700..706]:variation-location:"3p22.1"
;[709..712]:gene-rna:"APC"
;[715..741]:gene-rna:"adenomatous polyposis coli"
;[748..754]:variation-location:"5q22.2"
;[757..761]:gene-rna:"BTRC"
;[763..805]:gene-rna:"beta-transducin  repeat-containing protein"
;[812..819]:variation-location:"10q24.3"
;[825..829]:gene-rna:"ICAT"
;[831..867]:gene-rna:"inhibitor of beta-catenin and  Tcf-4"
;[869..875]:variation-location:"1p36.2"
(SENT
  (S
    (NP-SBJ (PRP:[527..529] We))
    (VP (VBD:[530..542] investigated)
      (NP (CD:[543..545] 37)
         (JJ:[546..555] malignant) (NNS:[557..566] melanomas)
        (PRN (-LRB-:[567..568] -LRB-)
          (NP
            (NP (CD:[568..570] 15)
               (JJ:[571..578] primary) (NNS:[579..585] tumors))
            (CC:[586..589] and)
            (NP (CD:[590..592] 22) (NNS:[593..603] metastases)))
          (-RRB-:[603..604] -RRB-)))
      (PP-PRP (IN:[605..608] for)
        (NP
          (NP (NNS:[609..620] alterations))
          (PP (IN:[621..623] of)
            (NP
              (NP (CD:[624..625] 4) (NNS:[626..631] genes))
              (VP (VBG:[633..641] encoding)
                (NP
                  (NP (NNS:[642..649] members))
                  (PP (IN:[650..652] of)
                    (NP
                      (NP (DT:[653..657] this) (NN:[658..665] pathway))
                      (,:[665..666] ,)
                      (NP
                        (ADVP (FW:[667..671] i.e.))
                        (,:[671..672] ,)
                        (NP (NN:[673..679] CTNNB1)
                          (PRN (-LRB-:[680..681] -LRB-)
                            (NP
                              (NML (NN:[681..693] beta-catenin)
                                   (NN:[694..698] gene))
                              (,:[698..699] ,) (NN:[700..706] 3p22.1))
                            (-RRB-:[706..707] -RRB-)))
                        (,:[707..708] ,)
                        (NP (NN:[709..712] APC)
                          (PRN (-LRB-:[714..715] -LRB-)
                            (NP
                              (NML
                                (NML (JJ:[715..726] adenomatous)
                                     (NN:[727..736] polyposis)
                                     (NN:[737..741] coli))
                                (NN:[742..746] gene))
                              (,:[746..747] ,) (NN:[748..754] 5q22.2))
                            (-RRB-:[754..755] -RRB-)))
                        (,:[755..756] ,)
                        (NP
                          (NP (NN:[757..761] BTRC)
                            (PRN (-LRB-:[762..763] -LRB-)
                              (NP
                                (NML
                                  (NML
                                    (ADJP
                                      (NML (NN:[763..778] beta-transducin)
                                           (NN:[780..786] repeat))
                                      (HYPH:[786..787] -)
                                       (VBG:[787..797] containing))
                                    (NN:[798..805] protein))
                                  (NN:[806..810] gene))
                                (,:[810..811] ,) (NN:[812..819] 10q24.3))
                              (-RRB-:[819..820] -RRB-)))
                          (CC:[821..824] and)
                          (NP (NN:[825..829] ICAT)
                            (PRN (-LRB-:[830..831] -LRB-)
                              (NP
                                (NP (NN:[831..840] inhibitor))
                                (PP (IN:[841..843] of)
                                  (NP
                                    (NML (NN:[844..856] beta-catenin)
                                         (CC:[857..860] and)
                                         (NN:[862..867] Tcf-4))
                                    (,:[867..868] ,) (NN:[869..875] 1p36.2))))
                              (-RRB-:[875..876] -RRB-))))))))))))))
    (.:[876..877] .)))

;sentence 6 Span:878..1017
;Mutational analysis of CTNNB1 identified somatic mutations in 1  primary
;melanoma and 1 melanoma metastasis from 2 different patients (5%).
;[901..907]:gene-rna:"CTNNB1"
;[927..936]:variation-event:"mutations"
;[943..959]:malignancy:"primary melanoma"
;[966..985]:malignancy:"melanoma metastasis"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[878..888] Mutational) (NN:[889..897] analysis))
      (PP (IN:[898..900] of)
        (NP (NN:[901..907] CTNNB1))))
    (VP (VBD:[908..918] identified)
      (NP (JJ:[919..926] somatic) (NNS:[927..936] mutations))
      (PP-LOC (IN:[937..939] in)
        (NP
          (NP
            (NP (CD:[940..941] 1)
               (JJ:[943..950] primary) (NN:[951..959] melanoma))
            (CC:[960..963] and)
            (NP (CD:[964..965] 1)
               (NN:[966..974] melanoma) (NN:[975..985] metastasis)))
          (PP (IN:[986..990] from)
            (NP (CD:[991..992] 2) (JJ:[993..1002] different)
                (NNS:[1003..1011] patients)
              (PRN (-LRB-:[1012..1013] -LRB-)
                (NP (CD:[1013..1014] 5) (NN:[1014..1015] %))
                (-RRB-:[1015..1016] -RRB-)))))))
    (.:[1016..1017] .)))

;sentence 7 Span:1018..1158
;Both  mutations affected the N-terminal degradation box of beta-catenin,
;which is  important for the regulation of beta-catenin homeostasis.
;[1024..1033]:variation-event:"mutations"
;[1047..1073]:variation-location:"N-terminal degradation box"
;[1077..1089]:gene-rna:"beta-catenin"
;[1133..1145]:gene-rna:"beta-catenin"
(SENT
  (S
    (NP-SBJ (DT:[1018..1022] Both) (NNS:[1024..1033] mutations))
    (VP (VBD:[1034..1042] affected)
      (NP
        (NP
          (NP (DT:[1043..1046] the)
            
            (NML (NN:[1047..1048] N) (HYPH:[1048..1049] -)
                 (JJ:[1049..1057] terminal))
            (NN:[1058..1069] degradation) (NN:[1070..1073] box))
          (PP (IN:[1074..1076] of)
            (NP (NN:[1077..1089] beta-catenin))))
        (,:[1089..1090] ,)
        (SBAR
          (WHNP-1 (WDT:[1091..1096] which))
          (S
            (NP-SBJ-1 (-NONE-:[1096..1096] *T*))
            (VP (VBZ:[1097..1099] is)
              (ADJP-PRD (JJ:[1101..1110] important)
                (PP (IN:[1111..1114] for)
                  (NP
                    (NP (DT:[1115..1118] the) (NN:[1119..1129] regulation))
                    (PP (IN:[1130..1132] of)
                      (NP (NN:[1133..1145] beta-catenin)
                          (NN:[1146..1157] homeostasis)))))))))))
    (.:[1157..1158] .)))

;sentence 8 Span:1159..1278
;Another primary  melanoma carried a somatic APC missense mutation within the
;known mutation  cluster region in exon 15.
;[1167..1184]:malignancy:"primary  melanoma"
;[1203..1206]:gene-rna:"APC"
;[1207..1224]:variation-type:"missense mutation"
;[1270..1277]:variation-location:"exon 15"
(SENT
  (S
    (NP-SBJ (DT:[1159..1166] Another)
       (JJ:[1167..1174] primary) (NN:[1176..1184] melanoma))
    (VP (VBD:[1185..1192] carried)
      (NP (DT:[1193..1194] a) (JJ:[1195..1202] somatic) (NN:[1203..1206] APC)
         (JJ:[1207..1215] missense) (NN:[1216..1224] mutation))
      (PP-LOC (IN:[1225..1231] within)
        (NP
          (NP (DT:[1232..1235] the) (VBN:[1236..1241] known)
            (NML (NN:[1242..1250] mutation) (NN:[1252..1259] cluster))
            (NN:[1260..1266] region))
          (PP (IN:[1267..1269] in)
            (NP (NN:[1270..1274] exon) (CD:[1275..1277] 15))))))
    (.:[1277..1278] .)))

;sentence 9 Span:1279..1347
;Fourteen tumors (40%) showed LOH at microsatellite  markers on 1p36.
;[1288..1294]:malignancy:"tumors"
;[1308..1311]:variation-type:"LOH"
;[1342..1346]:variation-location:"1p36"
(SENT
  (S
    (NP-SBJ (CD:[1279..1287] Fourteen) (NNS:[1288..1294] tumors)
      (PRN (-LRB-:[1295..1296] -LRB-)
        (NP (CD:[1296..1298] 40) (NN:[1298..1299] %))
        (-RRB-:[1299..1300] -RRB-)))
    (VP (VBD:[1301..1307] showed)
      (NP (NN:[1308..1311] LOH))
      (PP-LOC (IN:[1312..1314] at)
        (NP
          (NP (NN:[1315..1329] microsatellite) (NNS:[1331..1338] markers))
          (PP (IN:[1339..1341] on)
            (NP (NN:[1342..1346] 1p36))))))
    (.:[1346..1347] .)))

;sentence 10 Span:1348..1512
;None of the tumors had lost both copies of the ICAT gene, but 1  melanoma
;metastasis carried a somatic point mutation altering the translation  start
;codon of ICAT.
;[1360..1366]:malignancy:"tumors"
;[1395..1399]:gene-rna:"ICAT"
;[1413..1432]:malignancy:"melanoma metastasis"
;[1451..1465]:variation-type:"point mutation"
;[1492..1503]:variation-state-original:"start codon"
;[1507..1511]:gene-rna:"ICAT"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NN:[1348..1352] None))
        (PP (IN:[1353..1355] of)
          (NP (DT:[1356..1359] the) (NNS:[1360..1366] tumors))))
      (VP (VBD:[1367..1370] had)
        (VP (VBN:[1371..1375] lost)
          (NP
            (NP (DT:[1376..1380] both) (NNS:[1381..1387] copies))
            (PP (IN:[1388..1390] of)
              (NP (DT:[1391..1394] the) (NN:[1395..1399] ICAT)
                  (NN:[1400..1404] gene)))))))
    (,:[1404..1405] ,) (CC:[1406..1409] but)
    (S
      (NP-SBJ (CD:[1410..1411] 1)
         (NN:[1413..1421] melanoma) (NN:[1422..1432] metastasis))
      (VP (VBD:[1433..1440] carried)
        (NP
          (NP (DT:[1441..1442] a) (JJ:[1443..1450] somatic)
             (NN:[1451..1456] point) (NN:[1457..1465] mutation))
          (VP (VBG:[1466..1474] altering)
            (NP
              (NP (DT:[1475..1478] the)
                (NML (NN:[1479..1490] translation) (NN:[1492..1497] start))
                (NN:[1498..1503] codon))
              (PP (IN:[1504..1506] of)
                (NP (NN:[1507..1511] ICAT))))))))
    (.:[1511..1512] .)))

;sentence 11 Span:1513..1717
;Real-time RT-PCR showed markedly reduced ICAT transcript  levels (<or=20%
;relative to normal skin and benign melanocytic nevi) in 28/36  malignant
;melanomas (78%), including 13/14 tumors with LOH on 1p36.
;[1554..1558]:gene-rna:"ICAT"
;[1615..1638]:malignancy:"benign melanocytic nevi"
;[1650..1669]:malignancy:"malignant melanomas"
;[1693..1699]:malignancy:"tumors"
;[1705..1708]:variation-type:"LOH"
;[1712..1716]:variation-location:"1p36"
(SENT
  (S
    (NP-SBJ
      (NML (JJ:[1513..1517] Real) (HYPH:[1517..1518] -) (NN:[1518..1522] time))
      (NN:[1523..1525] RT) (HYPH:[1525..1526] -) (NN:[1526..1529] PCR))
    (VP (VBD:[1530..1536] showed)
      (NP
        (ADJP (RB:[1537..1545] markedly) (VBN:[1546..1553] reduced))
        (NN:[1554..1558] ICAT) (NN:[1559..1569] transcript)
         (NNS:[1571..1577] levels)
        (PRN (-LRB-:[1578..1579] -LRB-)
          (NP
            (QP (SYM:[1579..1580] <) (CC:[1580..1582] or) (SYM:[1582..1583] =)
                (CD:[1583..1585] 20))
            (NN:[1585..1586] %)
            (ADJP (JJ:[1587..1595] relative)
              (PP (TO:[1596..1598] to)
                (NP
                  (NP (JJ:[1599..1605] normal) (NN:[1606..1610] skin))
                  (CC:[1611..1614] and)
                  (NP (JJ:[1615..1621] benign) (JJ:[1622..1633] melanocytic)
                      (NNS:[1634..1638] nevi))))))
          (-RRB-:[1638..1639] -RRB-)))
      (PP-LOC (IN:[1640..1642] in)
        (NP
          (NP (CD:[1643..1645] 28))
          (PP (SYM:[1645..1646] /)
            (NP (CD:[1646..1648] 36)
              (NML (JJ:[1650..1659] malignant) (NNS:[1660..1669] melanomas))))
          (PRN (-LRB-:[1670..1671] -LRB-)
            (NP (CD:[1671..1673] 78) (NN:[1673..1674] %))
            (-RRB-:[1674..1675] -RRB-))
          (,:[1675..1676] ,)
          (PP (VBG:[1677..1686] including)
            (NP
              (NP (CD:[1687..1689] 13))
              (PP (SYM:[1689..1690] /)
                (NP
                  (NP (CD:[1690..1692] 14) (NNS:[1693..1699] tumors))
                  (PP (IN:[1700..1704] with)
                    (NP
                      (NP (NN:[1705..1708] LOH))
                      (PP-LOC (IN:[1709..1711] on)
                        (NP (NN:[1712..1716] 1p36))))))))))))
    (.:[1716..1717] .)))

;sentence 12 Span:1718..1771
;Allelic loss  on 10q was detected in 15 tumors (44%).
;[1718..1730]:variation-type:"Allelic loss"
;[1735..1738]:variation-location:"10q"
;[1758..1764]:malignancy:"tumors"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[1718..1725] Allelic) (NN:[1726..1730] loss))
      (PP-LOC (IN:[1732..1734] on)
        (NP (NN:[1735..1738] 10q))))
    (VP (VBD:[1739..1742] was)
      (VP (VBN:[1743..1751] detected)
        (NP-1 (-NONE-:[1751..1751] *))
        (PP-LOC (IN:[1752..1754] in)
          (NP (CD:[1755..1757] 15) (NNS:[1758..1764] tumors)
            (PRN (-LRB-:[1765..1766] -LRB-)
              (NP (CD:[1766..1768] 44) (NN:[1768..1769] %))
              (-RRB-:[1769..1770] -RRB-))))))
    (.:[1770..1771] .)))

;sentence 13 Span:1772..1872
;We found neither mutations nor complete  loss of expression of the BTRC gene
;in our melanoma series.
;[1789..1798]:variation-event:"mutations"
;[1839..1843]:gene-rna:"BTRC"
;[1856..1864]:malignancy:"melanoma"
(SENT
  (S
    (NP-SBJ (PRP:[1772..1774] We))
    (VP (VBD:[1775..1780] found)
      (NP
        (NP (CC:[1781..1788] neither)
          (NP
            (NP (NNS:[1789..1798] mutations))
            (PP-1 (-NONE-:[1798..1798] *RNR*)))
          (CC:[1799..1802] nor)
          (NP
            (NP (JJ:[1803..1811] complete) (NN:[1813..1817] loss))
            (PP (IN:[1818..1820] of)
              (NP
                (NP (NN:[1821..1831] expression))
                (PP-1 (-NONE-:[1831..1831] *RNR*))))))
        (PP-1 (IN:[1832..1834] of)
          (NP (DT:[1835..1838] the) (NN:[1839..1843] BTRC)
              (NN:[1844..1848] gene))))
      (PP (IN:[1849..1851] in)
        (NP (PRP$:[1852..1855] our) (NN:[1856..1864] melanoma)
            (NN:[1865..1871] series))))
    (.:[1871..1872] .)))

;sentence 14 Span:1873..2110
;Taken together, our  results indicate that the Wnt pathway may be altered in
;malignant melanomas by  different mechanisms, including rare somatic
;mutations in CTNNB1, APC or ICAT,  as well as low or absent expression of
;ICAT transcripts.
;[1920..1923]:gene-generic:"Wnt"
;[1950..1969]:malignancy:"malignant melanomas"
;[2032..2038]:gene-rna:"CTNNB1"
;[2040..2043]:gene-rna:"APC"
;[2047..2051]:gene-rna:"ICAT"
;[2093..2097]:gene-rna:"ICAT"
(SENT
  (S
    (S-ADV
      (NP-SBJ (-NONE-:[1873..1873] *))
      (VP (VBN:[1873..1878] Taken)
        (ADVP (RB:[1879..1887] together))))
    (,:[1887..1888] ,)
    (NP-SBJ (PRP$:[1889..1892] our) (NNS:[1894..1901] results))
    (VP (VBP:[1902..1910] indicate)
      (SBAR (IN:[1911..1915] that)
        (S
          (NP-SBJ-1 (DT:[1916..1919] the) (NN:[1920..1923] Wnt)
                    (NN:[1924..1931] pathway))
          (VP (MD:[1932..1935] may)
            (VP (VB:[1936..1938] be)
              (VP (VBN:[1939..1946] altered)
                (NP-1 (-NONE-:[1946..1946] *))
                (PP-LOC (IN:[1947..1949] in)
                  (NP (JJ:[1950..1959] malignant) (NNS:[1960..1969] melanomas)))
                (PP-MNR (IN:[1970..1972] by)
                  (NP
                    (NP (JJ:[1974..1983] different)
                        (NNS:[1984..1994] mechanisms))
                    (,:[1994..1995] ,)
                    (PP (VBG:[1996..2005] including)
                      (NP
                        (NP
                          (NP (JJ:[2006..2010] rare) (JJ:[2011..2018] somatic)
                              (NNS:[2019..2028] mutations))
                          (PP (IN:[2029..2031] in)
                            (NP
                              (NP (NN:[2032..2038] CTNNB1))
                              (,:[2038..2039] ,)
                              (NP (NN:[2040..2043] APC) (CC:[2044..2046] or)
                                  (NN:[2047..2051] ICAT)))))
                        (,:[2051..2052] ,)
                        (CONJP (RB:[2054..2056] as) (RB:[2057..2061] well)
                               (IN:[2062..2064] as))
                        (NP
                          (NP
                            (ADJP (JJ:[2065..2068] low) (CC:[2069..2071] or)
                                  (JJ:[2072..2078] absent))
                            (NN:[2079..2089] expression))
                          (PP (IN:[2090..2092] of)
                            (NP (NN:[2093..2097] ICAT)
                                (NNS:[2098..2109] transcripts))))))))))))))
    (.:[2109..2110] .)))

;section 15 Span:2111..2143
;Copyright 2002  Wiley-Liss, Inc.
(SEC
  (FRAG (NN:[2111..2120] Copyright) (CD:[2121..2125] 2002)
        (NNP:[2127..2132] Wiley) (HYPH:[2132..2133] -) (NNP:[2133..2137] Liss)
        (,:[2137..2138] ,) (NNP:[2139..2143] Inc.)))

;section 16 Span:2147..2192
;PMID: 12124804 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2147..2151] PMID) (::[2151..2152] :) (CD:[2153..2161] 12124804)
        (NN:[2162..2163] -LSB-) (NNP:[2163..2169] PubMed) (::[2170..2171] -)
        (NN:[2172..2179] indexed) (IN:[2180..2183] for)
        (NNP:[2184..2192] MEDLINE-RSB-)))
